Advanced search
Publication Cover
Modern Rheumatology Volume 27, 2017 - Issue 6
Journal homepage
304
Views
34
CrossRef citations to date
0
Altmetric
Original Article

Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: A multicenter retrospective observational study

Giuseppe LopalcoDepartment of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy;
,
Giacomo EmmiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy;
,
Stefano GentileschiResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy;
,
Silvana GuerrieroDepartment of Neurosciences and Sense Organs, University of Bari, Bari, Italy;
,
Antonio VitaleResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy;
,
Elena SilvestriDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy;
,
Matteo BecattiDepartment of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy;
,
Iacopo CavalloDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy;
,
Claudia FabianiDepartment of Ophthalmology, Humanitas Research Hospital, Milan, Italy
,
Bruno FredianiResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy;
,
Florenzo IannoneDepartment of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Bari, Italy;
&
Luca CantariniResearch Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy; Correspondence[email protected]
 show all
Pages 1031-1035 | Received 22 Dec 2016, Accepted 16 Jan 2017, Published online: 21 Feb 2017

References

  • Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease. Autoimmun Rev. 2015;14:1–9.
  • Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3:148–55.
  • Rotondo C, Lopalco G, Iannone F, Vitale A, Talarico R, Galeazzi M, et al. Mucocutaneous involvement in Behçet’s disease: how systemic treatment has changed in the last decades and future perspectives. Mediat Inflamm. 2015;2015:451675.
  • Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G. Evaluation of current therapeutic strategies in Behçet’s disease. Clin Rheumatol. 2011;30:157–63.
  • Lopalco G, Lucherini OM, Vitale A, Talarico R, Lopalco A, Galeazzi M, et al. Putative role of serum amyloid-A and proinflammatory cytokines as biomarkers for Behcet’s disease. Medicine (Baltimore). 2015;94:e1858.
  • Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet’s disease. Autoimmun Rev. 2012;11:699–704.
  • Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci. 2008;272:99–105.
  • Misumi M, Hagiwara E, Takeno M, Takeda Y, Inoue Y, Tsuji T, et al. Cytokine production profile in patients with Behcet’s disease treated with infliximab. Cytokine. 2003;24:210–8.
  • Pipitone N, Olivieri I, Padula A, D’angelo S, Nigro A, Zuccoli G, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285–90.
  • Perra D, Alba MA, Callejas JL, Mesquida M, Ríos-Fernández R, Adán A, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–31.
  • Cantarini L, Tinazzi I, Caramaschi P, Bellisai F, Brogna A, Galeazzi M. Safety and efficacy of etanercept in children with juvenile-onset Behcet’s disease. Int J Immunopathol Pharmacol. 2009;22:551–5.
  • Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, Álvarez-Castro C, Mesquida M, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediat Inflamm. 2014;2014:717598.
  • International Study Group for Behçet disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
  • Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behcet’s disease activity index. Rheumatology (Oxford). 2004;43:73–8.
  • Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–62.
  • Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.
  • Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
  • Cantarini L, Talarico R, Generali E, Emmi G, Lopalco G, Costa L, et al. Safety profile of biologic agents for Behçet’s disease in a multicenter observational cohort study. Int J Rheum Dis. 2015 [Epub ahead of print]. doi: 10.1111/1756-185X.12732.
  • Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160–2.
  • Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, et al. Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141–3.
  • Furuta S, Chow YW, Chaudhry AN, Jayne D. Switching of anti-TNF-α agents in Behçet’s disease. Clin Exp Rheumatol. 2012;30:S62–8.
  • Olivieri I, Leccese P, D’Angelo S, Padula A, Nigro A, Palazzi C, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29:S54–7.
  • Llorenç V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maíz O, et al. Certolizumab Pegol, a new anti-TNF-α in the armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016;24:167–72.
  • Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015;34:1293–301.
  • Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95:e3863.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.